6 Papers
30 Citations
Andrew King is an academic researcher from University Hospitals Birmingham NHS Foundation Trust. The author has contributed to research in topics: Liver disease & Granulocyte colony-stimulating factor. The author has an hindex of 5, co-authored 6 publications. Previous affiliations of Andrew King include University of Birmingham & Queen Elizabeth Hospital Birmingham.
Chat about Author
Papers
Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial
Philip N. Newsome,Philip N. Newsome,Richard Fox,Richard Fox,Andrew King,Andrew King,Darren Barton,Darren Barton,Nwe-Ni Than,Nwe-Ni Than,Joanna Moore,Chris Corbett,Sarah Townsend,James Thomas,Kathy Guo,Kathy Guo,Diana Hull,Diana Hull,Heather A Beard,Jacqui Thompson,Anne P.M. Atkinson,Carol Bienek,Neil W. A. McGowan,Neil Guha,John D.M. Campbell,Dan Hollyman,Deborah Stocken,Christina Yap,Stuart J. Forbes +28 more
TL;DR: G-CSF with or without haemopoietic stem-cell infusion did not improve liver dysfunction or fibrosis and might be associated with increased frequency of adverse events compared with standard care.
143
Sphingosine-1-Phosphate Prevents Egress of Hematopoietic Stem Cells From Liver to Reduce Fibrosis
Andrew King,Diarmaid D. Houlihan,Dean Kavanagh,Debashis Haldar,Nguyet Luu,Andrew Owen,Shankar Suresh,Nwe Ni Than,Gary M. Reynolds,Jasmine Penny,Henry Sumption,Prakash Ramachandran,Neil C. Henderson,Neena Kalia,Jon Frampton,David H. Adams,Philip N. Newsome +16 more
TL;DR: It is found that hematopoietic stem cells promote recruitment of endogenous macrophages and neutrophils in liver and this process to require C-C motif chemokine receptor 2 and HSCs to recruit monocytes.
61
REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial
Andrew King,Darren Barton,H A Beard,Nwe Ni Than,Joanna Moore,Chris Corbett,James Thomas,Kathy Guo,Indra Neil Guha,D Hollyman,Deborah D. Stocken,Christina Yap,Richard Fox,Stuart J. Forbes,Philip N. Newsome +14 more
TL;DR: This trial aims to demonstrate an improvement in the severity of liver disease over 3 months using either G-CSF alone or G- CSF followed by repeated infusions of haematopoietic stem cells compared with standard conservative management.
32
A case-controlled study of the safety and efficacy of transjugular intrahepatic portosystemic shunts after liver transplantation.
Andrew King,Andrew King,G. Masterton,Bridget Gunson,Bridget Gunson,Simon Olliff,Doris N. Redhead,Kamarjit Mangat,Gabriel C. Oniscu,Peter C. Hayes,Dhiraj Tripathi +10 more
TL;DR: TIPS insertion is feasible in transplant recipients, although its efficacy is lower in these patients versus control patients and outcomes are poor for OLT recipients with a pre‐TIPS MELD score > 15.
29
Assessment of the quality of evidence underlying international guidelines in liver disease.
Ian A. Rowe,Richard D. Parker,Matthew J. Armstrong,Andrew King,Diarmaid D. Houlihan,David Mutimer +5 more
TL;DR: Evidence-based recommendations in these guidelines are most frequently based on low-quality evidence, and recommendations revised to include high-qualityevidence accounted for only 16.3% of all new or updated recommendations.
24